[{"orgOrder":0,"company":"Educell","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CAR-T cell therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Educell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Educell \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Educell \/ Orgenesis"}]

Find Clinical Drug Pipeline Developments & Deals by Educell

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapi...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 14, 2020

                          Lead Product(s) : CAR-T cell therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Orgenesis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank